Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
PTIE's Cash-to-Debt is ranked higher than
95% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. PTIE: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PTIE' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
PTIE's Interest Coverage is ranked higher than
94% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PTIE: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PTIE' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 6.65
Beneish M-Score: -4.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -56.75
PTIE's ROE % is ranked lower than
67% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. PTIE: -56.75 )
Ranked among companies with meaningful ROE % only.
PTIE' s ROE % Range Over the Past 10 Years
Min: -61.87  Med: -9.37 Max: 102.69
Current: -56.75
-61.87
102.69
ROA % -52.22
PTIE's ROA % is ranked lower than
72% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. PTIE: -52.22 )
Ranked among companies with meaningful ROA % only.
PTIE' s ROA % Range Over the Past 10 Years
Min: -57.99  Med: -3.53 Max: 58.98
Current: -52.22
-57.99
58.98
ROC (Joel Greenblatt) % -5485.24
PTIE's ROC (Joel Greenblatt) % is ranked lower than
84% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. PTIE: -5485.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PTIE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -38255.38  Med: -3417.21 Max: 731.79
Current: -5485.24
-38255.38
731.79
3-Year Revenue Growth Rate -100.00
PTIE's 3-Year Revenue Growth Rate is ranked lower than
95% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. PTIE: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PTIE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 132.2
Current: -100
0
132.2
GuruFocus has detected 1 Warning Sign with Pain Therapeutics Inc $PTIE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PTIE's 30-Y Financials

Financials (Next Earnings Date: 2017-07-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PTIE Guru Trades in Q2 2016

Charles Brandes 78,758 sh (+108.80%)
First Eagle Investment 6,602,658 sh (+16.15%)
Jim Simons 799,787 sh (+10.01%)
Mario Gabelli 65,000 sh (unchged)
» More
Q3 2016

PTIE Guru Trades in Q3 2016

Jim Simons 910,187 sh (+13.80%)
First Eagle Investment 6,602,658 sh (unchged)
Mario Gabelli 65,000 sh (unchged)
Charles Brandes 53,200 sh (-32.45%)
» More
Q4 2016

PTIE Guru Trades in Q4 2016

Mario Gabelli 110,000 sh (+69.23%)
First Eagle Investment 6,602,658 sh (unchged)
Charles Brandes Sold Out
Jim Simons 836,187 sh (-8.13%)
» More
Q1 2017

PTIE Guru Trades in Q1 2017

First Eagle Investment 6,602,658 sh (unchged)
Mario Gabelli 110,000 sh (unchged)
Jim Simons 642,787 sh (-23.13%)
» More
» Details

Insider Trades

Latest Guru Trades with PTIE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:BIOAF, NAS:XBIO, OTCPK:IPATF, OTCPK:EMIS, NAS:MIRN, NAS:EARS, NAS:CSBR, AMEX:CRMD, NAS:ICCC, OTCPK:GBLX, OTCPK:NWBO, NAS:DFFN, NAS:TPIV, NAS:VKTX, OTCPK:RGRX, AMEX:CANF, NAS:DMTX, OTCPK:MRNA, NAS:CATB, NAS:MRNS » details
Traded in other countries:PX91.Germany,
Headquarter Location:USA
Pain Therapeutics Inc is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma.

Pain Therapeutics Inc a Delaware corporation was incorporated in May 1998. The Company is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. Its drug candidate is called REMOXY. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. REMOXY is a novel controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes novel excipients. The Company owns all commercial rights to its pipeline of drug candidates in oncology and hematology. It relies on a limited number of third-party manufacturers to formulate, manufacture, fill, label, ship or store all of its drug candidates. The company's strategies include Focus on Clinical Development Stage Products. It currently retains commercialization rights to all of its technology and drug candidates in all markets and indications, except for REMOXY and certain other abuse-resistant drugs. The Company has an exclusive Development and License Agreement, or the Durect Agreement, with Durect Corporation, or Durect, to use a patented technology that forms the basis for certain drug candidates, including REMOXY. Companies that currently sell generic or proprietary opioid formulations include, but are not limited to, Roxane Laboratories, Purdue Pharma, Pfizer, Abbott Laboratories, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals. The Company is subject to governmental regulations.

Top Ranked Articles about Pain Therapeutics Inc

Pain Therapeutics Announces Reverse Stock Split
Pain Therapeutics Reports First Quarter 2017 Financial Results
Pain Therapeutics Announces Positive Regulatory Guidance for REMOXY™ ER

- Company Will Host Conference Call on Tuesday, March 21st, at 8am Eastern Time -

AUSTIN, Texas, March 20, 2017 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (NASDAQ:PTIE) today announced positive regulatory guidance from a recent meeting with the U.S. Food and Drug Administration (FDA) regarding REMOXY (extended-release oxycodone capsules CII), its lead drug candidate.  The Company will host a conference call tomorrow morning at 8am EDT to discuss REMOXY, and to present a corporate update around partnership discussions and advances to its pipeline.
“In recent weeks we have worked closely with the FDA,” said Remi Barbier, President & CEO. “We appreciate their guidance, we understand their new requirements and we believe we’re now on track to make expeditious progress toward a resubmission of the REMOXY NDA.” Pain Therapeutics and the FDA met on February 13, 2017, to discuss REMOXY.  During this meeting, agreement was reached on additional studies that are needed for REMOXY’s approval.  We expect to complete these studies by year-end 2017, at a cost of approximately $3-4 million. Following completion of these studies, we intend to have a pre-NDA meeting with the FDA, followed by resubmission of the REMOXY NDA, with anticipated Priority Review, under 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Final Minutes of our FDA discussions confirm two requirements are needed for the resubmission of the REMOXY NDA: To conduct a clinical abuse potential study via the intranasal route of abuse; andTo conduct a non-clinical abuse potential study using household solvents. CLINICAL (INTRANASAL) ABUSE POTENTIAL STUDY
REMOXY has a sticky, high-viscosity gel formulation that cannot be snorted.   Therefore, our intranasal study will ask human volunteers to self-administer into their nostrils REMOXY, placebo or an active comparator.  Positive data in one intranasal study is adequate to support a label claim against the intranasal route of abuse.  We previously generated positive results using REMOXY under similar test conditions in a large animal model. NON-CLINICAL ABUSE POTENTIAL STUDY
REMOXY’s sticky, high-viscosity formulation cannot be pulled through a normal size syringe.  This feature makes it difficult to abuse REMOXY via simple injection.  Therefore, we will conduct an abuse potential study in a lab using thin films of REMOXY smeared on glass plates to assess how household solvents affect the formulation.  We plan to generate these data against comparator products.  Positive data in this study is adequate to support a label claim against the injection route of abuse.  We previously generated positive results using REMOXY under similar test conditions. Our recent discussions with the FDA did not raise any issues around safety, drug efficacy, manufacturing, stability or other drug development topics. Conference Call
We will host a conference call on Tuesday, March 21st, at 8am Eastern time to discuss REMOXY, and to present a corporate update around partnership discussions and advances to its pipeline.  To participate in this conference call in the U.S., please dial toll-free 1-877-407-4018 or international 1-201-689-8471. To hear the conference call live via the internet, please visit www.paintrials.com.  About two hours following the live call, a replay of the conference call will be available by phone through Friday, March 31, 2017.  To listen to a replay of the call, in the U.S. please dial toll-free 1-844-512-2921, or international 1-412-317-6671, and press replay number 13658173. About REMOXY ER (extended-release oxycodone capsules CII)
REMOXY is a proprietary, abuse-deterrent, extended-release oral formulation of oxycodone. The proposed indication for this drug candidate is for "the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate." We developed REMOXY to make oxycodone difficult to abuse yet provide 12 hours of steady pain relief when used appropriately by patients. REMOXY’s thick, sticky, high-viscosity gel formulation may deter unapproved routes of drug administration, such as injection, snorting or smoking.  REMOXY targets the multi-billion dollar marketplace for long-acting oxycodone. We own exclusive, worldwide commercial rights to REMOXY. About Opioid Abuse
Opioid drugs such as oxycodone are an important treatment option for patients with severe chronic pain.  However, oxycodone abuse and diversion remains a serious, persistent problem. Nearly 19,000 people died from opioid overdose in 2014, according to the National Institute on Drug Abuse.  For over a decade, Pain Therapeutics has pioneered Abuse-Deterrent Formulations (ADFs) to help in the fight against prescription drug abuse.  ADFs attempt to raise the bar on prescription drug abuse by making it difficult, longer or aversive to tamper with long-acting opioid formulations, recognizing that no drug can be made abuse-proof. About Pain Therapeutics, Inc.
We develop proprietary drugs that offer significant improvements to patients and physicians. Our expertise consists of developing new drugs and guiding these through various regulatory and development pathways in preparation for their eventual commercialization.  We generally focus our drug development efforts around disorders of the nervous system, such as chronic pain.  The FDA has not yet established the safety or efficacy of our drug candidates. NOTE: REMOXY is a trademark of Pain Therapeutics, Inc. Important Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding discussions with the FDA; the abuse-deterrent properties and potential benefits of REMOXY; progress towards a resubmission plan for the REMOXY NDA; and timing or estimated costs of studies and actions needed to resubmit the REMOXY NDA to the FDA. Such statements are based on management's current expectations but actual results may vary materially due to various factors, many of which are beyond the control of management. Drug development involves substantial risks and uncertainties, including but not limited to those risks and uncertainties relating to successfully completing the activities required to address the issues raised by the FDA in the September 2016 Complete Response Letter for REMOXY ER and the time required to do so, including the time required to conduct the studies and activities to be undertaken and the possibility that the FDA may raise additional issues in the future that were not raised in the past. In addition, the development of abuse-deterrent drug products is a young and still emerging area of drug development, with regulatory guidance that may be inconsistent, unclear or still in development. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. For further information regarding these and other risks related to our business, investors should consult our filings with the U.S. Securities and Exchange Commission.
For More Information Contact:
Peter S. Roddy 
Pain Therapeutics, Inc.           
[email protected]
(512) 501-2450

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.70
PTIE's PB Ratio is ranked higher than
71% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. PTIE: 1.70 )
Ranked among companies with meaningful PB Ratio only.
PTIE' s PB Ratio Range Over the Past 10 Years
Min: 0.58  Med: 3.74 Max: 15.26
Current: 1.7
0.58
15.26
EV-to-EBIT -0.93
PTIE's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. PTIE: -0.93 )
Ranked among companies with meaningful EV-to-EBIT only.
PTIE' s EV-to-EBIT Range Over the Past 10 Years
Min: -5139.8  Med: 8.85 Max: 17019.8
Current: -0.93
-5139.8
17019.8
EV-to-EBITDA -0.93
PTIE's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. PTIE: -0.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTIE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -930.2  Med: 22.95 Max: 1160.5
Current: -0.93
-930.2
1160.5
Current Ratio 19.69
PTIE's Current Ratio is ranked higher than
96% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. PTIE: 19.69 )
Ranked among companies with meaningful Current Ratio only.
PTIE' s Current Ratio Range Over the Past 10 Years
Min: 5.33  Med: 11.1 Max: 61.08
Current: 19.69
5.33
61.08
Quick Ratio 19.69
PTIE's Quick Ratio is ranked higher than
96% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. PTIE: 19.69 )
Ranked among companies with meaningful Quick Ratio only.
PTIE' s Quick Ratio Range Over the Past 10 Years
Min: 5.33  Med: 11.1 Max: 61.08
Current: 19.69
5.33
61.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.50
PTIE's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. PTIE: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTIE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.7  Med: -2 Max: 1.6
Current: -0.5
-17.7
1.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.73
PTIE's Price-to-Net-Cash is ranked higher than
83% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. PTIE: 1.73 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PTIE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.07  Med: 4.09 Max: 30.41
Current: 1.73
1.07
30.41
Price-to-Net-Current-Asset-Value 1.72
PTIE's Price-to-Net-Current-Asset-Value is ranked higher than
84% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. PTIE: 1.72 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PTIE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.06  Med: 4.02 Max: 11.89
Current: 1.72
1.06
11.89
Price-to-Tangible-Book 1.69
PTIE's Price-to-Tangible-Book is ranked higher than
77% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. PTIE: 1.69 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PTIE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.02  Med: 3.92 Max: 11.6
Current: 1.69
1.02
11.6
Earnings Yield (Greenblatt) % -106.81
PTIE's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. PTIE: -106.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PTIE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -106.81  Med: 2 Max: 18.6
Current: -106.81
-106.81
18.6

More Statistics

EPS (TTM) $ -0.27
Beta1.45
Short Percentage of Float9.21%
52-Week Range $3.57 - 21.00
Shares Outstanding (Mil)6.59

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -2.45 -3.85 -5.25
EPS without NRI ($) -2.45 -3.85 -5.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PTIE

Headlines

Articles On GuruFocus.com
Pain Therapeutics Announces Reverse Stock Split May 08 2017 
Pain Therapeutics Reports First Quarter 2017 Financial Results Apr 25 2017 
Pain Therapeutics Announces Positive Regulatory Guidance for REMOXY™ ER Mar 20 2017 
Wednesday Pre-Market Insights: GEVO, WPZ, HDP, PTIE May 13 2015 
Eveillard's First Eagle Increases 2 Positions Sep 11 2014 
Morning Coffee: Real-Time Picks May 14 2014 
Pain Therapeutics Reports Operating Results (10-K) Feb 03 2011 
Pain Therapeutics Reports Operating Results (10-Q) Oct 29 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 50,000 Shares Oct 04 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 28,597 Shares Sep 08 2010 

More From Other Websites
Pain Therapeutics Announces Reverse Stock Split May 08 2017
Pain Therapeutics reports 1Q loss Apr 25 2017
Pain Therapeutics Reports First Quarter 2017 Financial Results Apr 25 2017
Pain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE,EGLT) Mar 21 2017
Pain Therapeutics Announces Positive Regulatory Guidance for REMOXY™ ER Mar 20 2017
Here’s What The Latest Pain Therapeutics, Inc. (PTIE) Update Means Feb 21 2017
Pain Therapeutics, Inc. (PTIE): How Does It Compare Against Its Peers? Dec 16 2016
Durect (DRRX) Exited Third Quarter with Strong Balance Sheet Nov 01 2016
Pain Therapeutics (PTIE) Enters Oversold Territory Sep 29 2016
Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug Sep 28 2016
Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection Sep 26 2016
GW Pharmaceuticals (GWPH), Sally Beauty Holdings Inc. (SBH) & More: Why These Stocks Are Making... Sep 26 2016
For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million Sep 26 2016
Is Pain Therapeutics an Incredible Momentum Stock? 3 Reasons Why PTIE Will Be Tough to Beat Sep 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)